Humacyte Releases Five-Year Analysis Showing Average Hospital Charges of $316,600 for Extremity Arterial Injury
Humacyte announced the results of a five-year retrospective analysis of hospital charges, payer costs, and healthcare resource utilization in patients with extremity arterial injury. The average hospital charge for extremity arterial injury repair during initial hospitalization was $316,600 per patient, and amputations and infections increased the average hospital charge per patient by $492,986 and $589,921, respectively. Humacyte's Symvess has consistently demonstrated low rates of conduit infection and high rates of limb salvage in the treatment of extremity arterial injury. The company said, "Symvess offers an alternative to the high costs of complications from extremity arterial injury that occur when vein is not feasible for repair. As previously reported in JAMA Surgery, in clinical study Symvess's rate of infection was one-ninth that of synthetic graft historical controls, and Symvess's amputation rate was one-fifth that of historical controls."
Trade with 70% Backtested Accuracy
Analyst Views on HUMA
About HUMA
About the author
BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their market endeavors.
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
